PILRA (Paired Immunoglobulin-Like Type 2 Receptor Alpha), also known as PILRα, is an inhibitory immune receptor expressed primarily on cells of the immune system. The gene is located on chromosome 7q22.1 and encodes a type I transmembrane protein belonging to the paired immunoglobulin-like receptor family. PILRα plays critical roles in immune regulation by modulating the activation of various immune cell types, including T cells, natural killer (NK) cells, dendritic cells, and macrophages. This receptor has been extensively studied for its role in immune cell signaling and has recently gained attention for its involvement in neurodegenerative diseases.
In the central nervous system, PILRα is expressed on microglia, the resident immune cells of the brain, where it regulates neuroinflammatory responses. Recent genetic studies have identified PILRA variants associated with increased risk for Alzheimer's disease and Parkinson's disease, highlighting its importance in neurodegeneration . The receptor interacts with CD99 and other ligands to modulate immune responses, making it a potential therapeutic target for neuroinflammatory conditions.
| Property |
Value |
| Gene Symbol |
PILRA |
| Full Name |
Paired Immunoglobulin-Like Type 2 Receptor Alpha |
| Chromosomal Location |
7q22.1 |
| NCBI Gene ID |
9317 |
| OMIM ID |
604866 |
| Ensembl ID |
ENSG00000137216 |
| UniProt ID |
Q9YH5Q |
| Encoded Protein |
Paired immunoglobulin-like receptor alpha |
| Gene Type |
Protein-coding |
| Protein Family |
Paired immunoglobulin-like receptor family |
| Associated Diseases |
Alzheimer's disease, Parkinson's disease, multiple sclerosis, inflammatory disorders |
¶ Structure and Function
PILRα is a type I transmembrane glycoprotein with characteristic features:
- Extracellular domain: Contains two immunoglobulin-like domains for ligand binding
- Transmembrane region: Single pass helix anchor
- Cytoplasmic tail: Contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
The extracellular region consists of two immunoglobulin-like domains that mediate binding to various ligands, including CD99 and glycosylated ligands. The cytoplasmic tail contains ITIM sequences that, upon receptor engagement, recruit phosphatases (SHP-1, SHP-2) to transmit inhibitory signals.
¶ Protein Topology and Domains
The detailed domain structure of PILRα includes:
| Domain |
Position |
Function |
| Signal peptide |
1-19 |
Targeting to plasma membrane |
| Ig-like V-type domain 1 |
20-110 |
First ligand-binding domain |
| Ig-like C2-type domain |
111-190 |
Second ligand-binding domain |
| Transmembrane region |
191-213 |
Membrane anchoring |
| ITIM motif 1 |
241-246 |
Inhibitory signaling (YXXL/V) |
| ITIM motif 2 |
262-267 |
Secondary inhibitory motif |
PILRα functions as an inhibitory immune receptor:
- Inhibitory signaling: ITIM-mediated suppression of immune cell activation
- Ligand binding: Binds to CD99 and other potential ligands
- Immune modulation: Regulates inflammatory responses
- Cell-cell interactions: Mediates immune cell crosstalk
- Phagocytosis regulation: Modulates phagocytic activity of macrophages and microglia
- Cytokine production control: Regulates pro-inflammatory cytokine synthesis
ITIM-Mediated Inhibition:
- Ligand binding induces ITIM phosphorylation
- SHP-1 and SHP-2 phosphatases are recruited
- Downstream activation signals are suppressed
- Immune responses are modulated
SHP-1/SHP-2 Signaling Cascade:
flowchart TD
A["PILRα Ligand Binding"] --> B["ITIM Phosphorylation"]
B --> C["SHP-1/SHP-2 Recruitment"]
C --> D["Dephosphorylation of Akt"]
C --> D1["Dephosphorylation of Syk"]
D --> E["Reduced mTOR Signaling"]
D1 --> F["Reduced NF-κB Activation"]
E --> G["Inhibited Cell Proliferation"]
F --> H["Reduced Cytokine Production"]
Cross-talk with Activating Receptors:
PILRα often operates in concert with activating receptors to fine-tune immune responses. The balance between inhibitory and activating signals determines cellular responses. This is particularly important in microglia where PILRα modulates the response to amyloid-beta and alpha-synuclein.
Modulation of TREM2 Signaling:
Recent research suggests PILRα may interact with TREM2, another important microglial receptor involved in neurodegeneration. The interplay between these receptors may determine microglial phenotypic responses in AD and PD.
PILRA has emerged as an important genetic risk factor for Alzheimer's disease:
Genetic Association:
- PILRA variants have been associated with AD risk in genome-wide studies
- Certain PILRA alleles increase susceptibility to AD
- The functional variants affect receptor expression and function
- GWAS hits in PILRA region have been replicated in multiple cohorts
- The rs2075650 locus shows consistent association with AD risk
Specific Variants:
| Variant |
Effect |
Population |
| rs2075650 |
Increased AD risk |
European |
| rs1895192 |
Altered expression |
Multiple |
| rs2458323 |
Regulatory effect |
Asian |
Microglial Regulation:
PILRα is critical for microglial function in AD :
- Regulates microglial activation states
- Modulates cytokine production
- Affects phagocytic activity
- Influences amyloid plaque interaction
- Controls complement system interaction
Amyloid Pathology:
- PILRα affects microglial responses to amyloid-β
- Modulates Aβ clearance mechanisms
- Influences plaque-associated inflammation
- Affects Aβ aggregation kinetics
Neuroinflammation:
- PILRα regulates chronic neuroinflammation in AD
- Controls pro-inflammatory cytokine production
- Affects microglial survival and function
- Modulates NLRP3 inflammasome activity
Tau Pathology:
- PILRα may influence tau phosphorylation
- Microglial-mediated neuronal damage affects tau spread
- Interaction with complement system affects tau clearance
In Parkinson's disease, PILRα plays important roles:
Dopaminergic Neuron Protection:
- PILRα is expressed on microglia surrounding dopaminergic neurons
- Regulates neuroinflammatory responses
- May influence dopaminergic neuron survival
- Modulates microglial surveillance of substantia nigra
α-Synuclein Pathology:
PILRα is involved in the response to α-synuclein pathology :
- Modulates microglial responses to α-synuclein
- Affects aggregation and clearance
- Influences neuroinflammation in PD
- May affect Lewy body formation
Neuroinflammation:
- PILRα regulates chronic neuroinflammation
- Controls microglial activation
- Affects cytokine production
- Modulates T cell infiltration
PILRα has been implicated in multiple sclerosis:
- Modulates T cell responses
- Affects immune cell trafficking
- Regulates demyelination processes
- May influence lesion formation
- PILRα in microglial responses
- May affect motor neuron survival
- Modulates neuroinflammation in ALS
- Potential biomarker value
Huntington's Disease:
- PILRα expression altered in HD
- May modulate mutant huntingtin responses
- Microglial activation affected
Frontotemporal Dementia:
- Role in tauopathy contexts
- Microglial involvement
- Inflammatory modulation
Prion Diseases:
- PILRα in prion-induced neurodegeneration
- Immune response modulation
T Cells:
- PILRα inhibits T cell activation through ITIM signaling
- Modulates TCR signaling by recruiting SHP phosphatases
- Regulates cytokine production in activated T cells
- Influences T cell differentiation into various subsets
- Controls regulatory T cell function
Natural Killer Cells:
- Controls NK cell cytotoxicity through inhibitory signaling
- Modulates cytokine secretion (IFN-γ, TNF-α)
- Affects NK cell maturation and activation state
- Regulates interaction with target cells
Dendritic Cells:
- Regulates antigen presentation to T cells
- Modulates T cell priming and polarization
- Controls cytokine production affecting adaptive immunity
- Affects dendritic cell migration and maturation
Macrophages:
- Controls inflammatory responses to various stimuli
- Affects phagocytosis of pathogens and debris
- Regulates cytokine production (TNF-α, IL-6, IL-12)
- Modulates oxidative burst and antimicrobial activity
PILRα integrates with multiple signaling networks:
flowchart TD
A["PILRα Activation"] --> B["ITIM Phosphorylation"]
B --> C["SHP-1/SHP-2 Recruitment"]
C --> D["Multiple Downstream Effects"]
D --> E["MAPK Pathway"]
D --> F["PI3K/Akt Pathway"]
D --> G["NF-κB Pathway"]
D --> H["STAT Pathway"]
E --> E1["Reduced Proliferation"]
F --> F1["Altered Survival"]
G --> G1["Reduced Inflammation"]
H --> H1["Gene Expression Changes"]
Key Signaling Cross-talk Points:
- PI3K/Akt: SHP-mediated dephosphorylation reduces Akt activation
- MAPK: Decreased ERK and p38 activation
- NF-κB: Reduced IKK activation and nuclear translocation
- STAT: Modulated STAT phosphorylation patterns
Activation States:
PILRα regulates microglial polarization:
- Pro-inflammatory (M1) vs. anti-inflammatory (M2) states
- Cytokine production patterns
- Phagocytic capacity
- Antigen presentation capability
Phenotypic Regulation:
flowchart TD
A["PILRα Activation"] --> B{"Context Dependent"}
B -->|"Anti-inflammatory"| C["M2 Polarization"]
B -->|"Pro-inflammatory"| D["M1 Suppression"]
C --> E["IL-10 Production"]
C --> F["TGF-β Release"]
C --> G["Tissue Repair"]
D --> H["Reduced TNF-α"]
D --> I["Reduced IL-1β"]
D --> J["Limited NO Production"]
Neuroinflammation:
- Controls chronic neuroinflammation
- Affects cytokine and chemokine production
- Modulates cell-cell interactions
- Regulates inflammasome activation
- Controls reactive oxygen species production
Phagocytosis Regulation:
PILRα significantly modulates microglial phagocytosis:
- Affects complement-mediated clearance
- Modulates Fc receptor function
- Influences apoptotic cell clearance
- Regulates amyloid phagocytosis
¶ Cytokine and Chemokine Regulation
PILRα modulates production of various inflammatory mediators:
| Mediator |
Effect |
Pathway |
| TNF-α |
Downregulated |
NF-κB inhibition |
| IL-1β |
Downregulated |
NLRP3 modulation |
| IL-6 |
Variable |
Context-dependent |
| IL-10 |
Upregulated |
Anti-inflammatory |
| CCL2 |
Downregulated |
Reduced monocyte recruitment |
| CXCL10 |
Modulated |
IFN-γ pathway |
PILRA exhibits specific expression patterns across immune cell types:
| Cell Type |
Expression Level |
Functional Implication |
| T cells |
High |
Immune regulation, T cell inhibition |
| NK cells |
High |
Cytotoxicity control, cytokine modulation |
| Dendritic cells |
Moderate |
Antigen presentation, T cell priming |
| Macrophages |
Moderate |
Inflammation control, phagocytosis |
| B cells |
Low |
B cell function regulation |
| Monocytes |
Moderate |
Innate immune response |
| Neutrophils |
Low |
Inflammatory responses |
In the central nervous system, PILRα shows distinct expression patterns:
- Microglia: Primary immune cell expressing PILRα in brain, high levels in resting and activated states
- Neurons: Low to moderate expression, higher in certain neuronal populations
- Astrocytes: Limited expression, variable across brain regions
- Oligodendrocytes: Low expression, potential role in myelin maintenance
- Endothelial cells: Moderate expression, blood-brain barrier interaction
PILRA is expressed in various peripheral tissues:
- Spleen: High expression, immune cell populations
- Lymph nodes: Moderate expression, adaptive immune regulation
- Blood: Peripheral immune cells, particularly on monocytes and lymphocytes
- Bone marrow: Hematopoietic cell expression
- Brain: Microglial expression, neuroimmune function
- Lung: Resident immune cells
- Gut: Intestinal immune populations
PILRA expression varies across development:
- Embryonic development: Low expression in developing brain
- Postnatal development: Increasing expression as immune system matures
- Adult brain: Sustained expression, particularly in microglia
- Aging: Altered expression patterns with age
- Disease: Dysregulated expression in neurodegeneration
Therapeutic Strategies:
- Agonists: Activate inhibitory signaling to reduce neuroinflammation
- Antagonists: Block inhibitory signals when enhanced immunity is needed
- Gene therapy: Modulate expression levels
- RNAi approaches: Knockdown of PILRA expression
- Antisense oligonucleotides: Modulate PILRA translation
- Small molecule modulators: Target the receptor directly
¶ Preclinical and Clinical Studies
Animal Models:
- Pilra knockout mice show increased inflammatory responses
- Knockout models demonstrate enhanced amyloid clearance
- Studies in PD models show altered alpha-synuclein handling
Human Studies:
- PILRA genetic variants associated with AD risk
- Expression studies in AD and PD brain tissue
- CSF biomarker studies investigating PILRA levels
- Immune modulation: Balancing inflammation control without compromising host defense
- BBB penetration: Drug delivery to brain
- Specificity: Avoiding off-target effects on other immune receptors
- Timing: Determining optimal intervention window
- Biomarkers: Need for response monitoring markers
Small Molecule Modulators:
- Synthetic compounds targeting PILRα are under development
- Allosteric modulators may provide subtype specificity
Antibody-Based Therapies:
- Monoclonal antibodies against PILRα
- Engineered antibody fragments for brain delivery
- Bispecific antibodies targeting PILRα and pathological proteins
Gene Editing:
- CRISPR-based approaches to modify PILRA
- Epigenetic modulation of PILRA expression
- Viral vector-mediated gene delivery
- Flow cytometry: Surface expression on immune cells
- qPCR: mRNA expression
- Western blot: Protein detection
- Immunohistochemistry: Tissue localization
- ELISA: Soluble PILRα measurement in body fluids
- Mass spectrometry: Proteomic analysis
- Single-cell RNA-seq: Cellular expression patterns
- Knockout mice: Pilra-/- models
- Transgenic models: PILRA overexpression
- iPSC-derived microglia: Human models
- Brain organoids: Three-dimensional neural models
- Primary microglial cultures: In vitro studies
- PILRA knockout mice: Available from Jackson Laboratory
- Human iPSC lines: Various disease backgrounds
- Biobank samples: Brain tissue and CSF
- GWAS datasets: PILRA variant information
| Protein |
Interaction Type |
Functional Consequence |
| CD99 |
Ligand binding |
Immune regulation, T cell activation |
| SHP-1 |
ITIM recruitment |
Inhibitory signaling, dephosphorylation |
| SHP-2 |
ITIM recruitment |
Inhibitory signaling, cell survival |
| Amyloid-β |
Pathological ligand |
AD pathology, microglial activation |
| α-Synuclein |
Pathological ligand |
PD pathology, aggregation |
| TREM2 |
Receptor cross-talk |
Microglial phenotype determination |
| Complement proteins |
Interaction |
Phagocytosis regulation |
PILRA shows promise as a biomarker for neurodegenerative diseases:
Diagnostic Biomarkers:
- Soluble PILRα levels in CSF correlate with disease stage
- Peripheral blood PILRA expression as potential screening tool
- PILRA genetic variants as risk stratification markers
Prognostic Biomarkers:
- PILRA expression levels predict disease progression
- Variant analysis informs patient stratification for clinical trials
Therapeutic Biomarkers:
- PILRA levels as treatment response indicators
- Target engagement markers for PILRα-directed therapies
¶ Clinical Trials and Drug Development
Current Status:
- No PILRA-targeted drugs in clinical trials for neurodegeneration
- Preclinical development of modulators ongoing
- Repurposing of existing immunomodulators being explored
Clinical Development Considerations:
- Patient selection based on PILRA genotype
- Biomarker-driven enrollment strategies
- Combination approaches with existing therapies
- Long-term safety monitoring requirements
PILRA polymorphisms influence drug response:
| Genotype |
Drug Response |
Clinical Implication |
| Variant 1 |
Increased efficacy |
May benefit from PILRα agonists |
| Variant 2 |
Reduced response |
Alternative pathways needed |
| Wild-type |
Standard response |
Standard dosing applicable |
PILRA-based stratification for clinical trials:
- Genotype-guided patient selection
- Expression-based subtyping
- Integration with other biomarkers